Myriad hit with gene testing suit

14-10-2013

Myriad hit with gene testing suit

US biotech company Myriad Genetics is facing claims that 14 of its patents covering tests for breast and ovarian cancer are invalid and non-infringed by Quest Diagnostics.


myriad genetics, quest diagnostics, brca1, brca2, aclu

WIPR